

**IN THE CLAIMS:**

This listing of claims will replace all prior versions, and listing of the claims in the application.

**Listing of Claims:**

Claim 8 (currently amended): A modified recombinant allergen wherein at least one of the T-cell reactive regions 16-42, 135-149 and 180-206 of the Ph1 p 5b polypeptide of SEQ ID NO: 87, consisting of a total of 265 amino acids, is not altered.

Claim 9 (currently amended): A modified recombinant allergen according to claim 8, selected from the group consisting of:

PM1	(N <sup>32</sup> → D, D <sup>49</sup> → L, K <sup>50</sup> → A)	(SEQ ID NO. 88)
PM2	(D <sup>49</sup> → L, K <sup>50</sup> → A)	(SEQ ID NO. 89)
PM3	(A <sup>13</sup> → C)	(SEQ ID NO. 90)
DM1	(Δ K <sup>50</sup> → P <sup>Δ132</sup> , D <sup>49</sup> → L)	(SEQ ID NO. 91)
DM2	(Δ F <sup>51</sup> - G <sup>178</sup> , D <sup>49</sup> - L, K <sup>50</sup> - A)	(SEQ ID NO. 92)
DM2*	(Δ F <sup>51</sup> - G <sup>178</sup> , 179 - 217 altered sequence) or <u>and</u>	
DM3	(Δ A <sup>154</sup> - T <sup>177</sup> , A <sup>220</sup> → T)	(SEQ ID NO. 93).

Claim 10 (withdrawn).

Claim 11 (previously amended): A pharmaceutical preparation for treating an IgE-mediated allergy comprising at least one modified recombinant allergen according to claim 8 and a pharmaceutically acceptable carrier.

Claim 12 (withdrawn).

Claim 13 (withdrawn).

Claim 14 (withdrawn).

Claim 15 (previously added): The pharmaceutical preparation according to claim 11 comprising a physiologically compatible salt or solvate of said recombinant modified allergen.

Claim 16 (previously added): The pharmaceutical preparation according to claim 11 comprising an additional active compound.

Claim 17 (currently amended): A modified recombinant allergen having a region which corresponds to at least one of the T-cell reactive regions 16-42, 135-149, and 180-206 of the Ph1 p 5b polypeptide of SEQ ID NO: 87, consisting of a total of 265 amino acids, wherein at least one of said regions is not altered.

Claim 18 (previously added): A modified recombinant allergen of claim 17, wherein a combination of said regions is present and is not altered.

Claim 19 (currently amended): A modified recombinant allergen according to claim 17, selected from the group consisting of:

PM1           (N<sup>32</sup> → D, D<sup>49</sup> → L, K<sup>50</sup> → A)       (SEQ ID NO. 88)

PM2           (D<sup>49</sup> → L, K<sup>50</sup> → A)                   (SEQ ID NO. 89)

DM1           (Δ K<sup>50</sup> → P<sup>Δ132</sup>, D<sup>49</sup> → L)       (SEQ ID NO. 91) or and

DM3           (Δ A<sup>154</sup> - T<sup>177</sup>, A<sup>220</sup> → T)       (SEQ ID NO. 93).

Claim 20 (currently amended): The modified recombinant allergen according to claim 8, wherein "modified" said modification refers to a wild type polypeptide that is altered by a substitution.

Claim 21 (currently amended): The modified recombinant allergen according to claim 17, wherein "modified" said modification refers to a wild type polypeptide that is altered by a deletion.

Claim 22 (previously added): An allergen of claim 8, wherein a combination of said regions is present and is not altered.

23. (withdrawn):